Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration

被引:14
作者
Gilson, Marta M.
Bressler, Neil M.
Jabs, Douglas A.
Solomon, Sharon D.
Thorne, Jennifer E.
Wilson, David J.
机构
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Oregon Hlth & Sci Univ, Portland, OR USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
关键词
D O I
10.1016/j.ophtha.2007.03.071
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate fluorescein angiographic and visual acuity (VA) outcomes from patients enrolled in a trial of a single periocular corticosteroid injection immediately before photodynamic therapy (PDT) versus PDT alone for subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD). Design: Randomized 2-center clinical trial. Participants: Sixty-seven subjects with AMD, subfoveal choroidal neovascularization, and best-corrected VA of 20/20 to 20/320 in the study eye who had received no more than 1 prior PDT treatment. Methods: Subjects were randomized to receive PDT alone (no corticosteroid) or a single periocular corticosteroid injection given via the posterior superior sub-Tenon's capsule route before PDT (corticosteroid) and assessed 1, 3, and 6 months after enrollment. Best-corrected VA and intraocular pressure (IOP) measurements were taken during each examination. Color photographs and fluorescein angiograms were taken at baseline and 3 and 6 months. Main Outcome Measure: Presence or absence of fluorescein leakage from choroidal neovascularization 3 months after randomization. Results: Between the 34 participants randomized to periocular corticosteroid and 33 to no corticosteroid, baseline features appeared balanced. Thirty-three corticosteroid participants and 30 no corticosteroid participants returned for the 3-month follow-up, at which time 56 had fluorescein leakage. Proportions of participants with leakage at 3 months for the 2 treatment groups did not statistically significantly differ; 94% of the corticosteroid group and 90% of the no corticosteroid group had fluorescein leakage at 3 months (P = 0.66). Mean VAs at 3 months after enrollment were 20/100 and 20/125 in the corticosteroid and no corticosteroid groups, respectively, decreasing on average 1.5 and 0.9 lines from baseline (P = 0.50). Adverse events included IOP > 21 mmHg in 7 corticosteroid participants (21%) and 1 (3%) no corticosteroid participant (P < 0.05) and ptosis of the study eyelid in 1 (3%) corticosteroid participant. Conclusions: In contrast to previously reported uncontrolled studies and 1 controlled study, this trial did not find a reduction in the amount of fluorescein leakage 3 months after a single periocular injection of corticosteroid and PDT compared with PDT alone. Ophthalmology 2007,114:1713-1721 (c) 2007 by the American Academy of Ophthalmology.
引用
收藏
页码:1713 / 1721
页数:9
相关论文
共 37 条
[1]  
Arnold J, 2001, AM J OPHTHALMOL, V131, P541
[2]   Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials - TAP and VIP report no. 3 [J].
Arnold, JJ ;
Blinder, KJ ;
Bressler, M ;
Bressler, SB ;
Burdan, A ;
Haynes, L ;
Lim, JI ;
Miller, JW ;
Potter, MJ ;
Reaves, A ;
Rosenfeld, PJ ;
Sickenberg, M ;
Slakter, JS ;
Soubrane, G ;
Strong, HA ;
Stur, M .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (04) :683-696
[3]  
Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
[4]   Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1 [J].
Blinder, KJ ;
Bradley, S ;
Bressler, NM ;
Bressler, SB ;
Donati, G ;
Hao, Y ;
Ma, C ;
Menchini, U ;
Miller, J ;
Potter, MJ ;
Pournaras, JC ;
Reaves, A ;
Rosenfeld, PJ ;
Strong, HA ;
Stur, M ;
Su, XY ;
Virgili, G .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (03) :407-418
[5]   Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial [J].
Bonini, MA ;
Jorge, R ;
Barbosa, JC ;
Calucci, D ;
Cardillo, JA ;
Costa, RA .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (10) :3845-3849
[6]  
Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
[7]  
Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
[8]   Comparison of intravitreal versus posterior sub-tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema [J].
Cardillo, JA ;
Melo, LAS ;
Costa, RA ;
Skaf, M ;
Belfort, R ;
Souza-Filho, AA ;
Farah, ME ;
Kuppermann, BD .
OPHTHALMOLOGY, 2005, 112 (09) :1557-1563
[9]   Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up [J].
Challa, JK ;
Gillies, MC ;
Penfold, PL ;
Gyory, JF ;
Hunyor, ABL ;
Billson, FA .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, 1998, 26 (04) :277-281
[10]   Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model [J].
Ciulla, TA ;
Criswell, MH ;
Danis, RP ;
Hill, TE .
ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (03) :399-404